Gutless Adenoviral Vectors – Promising Tools for Gene Therapy
„Gutless”-Adenoviren – ein vielversprechender Vektor für die Gentherapie
Alicja Jozkowicz
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Dulak
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Nanobashvili
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorP. Polterauer
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorM. Prager
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorI. Huk
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorAlicja Jozkowicz
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Dulak
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorJ. Nanobashvili
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorP. Polterauer
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorM. Prager
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorI. Huk
From the 1 Division of Vascular Surgery, Department of Surgery, University of Vienna, the 2 Department of Cell Biochemistry, Department of Molecular Genetics, Institute of Molecular Biology, Jagiellonian University, Kraków, Poland, the 3 Division of Cardiology, Department of Internal Medicine, University of Innsbruck, and the 4 Ludwig Boltzmann Research Institute for Interdisciplinary Vascular Medicine, Vienna
Search for more papers by this authorAbstract
enSummary: Background: Progress in gene therapy depends on establishing the appropriate gene transfer methods. The most efficient vehicles for the delivery of foreign genes to the target tissues are modified adenoviruses. Methods: Adenoviral vectors of the first generation despite the high infection efficiency, have an essential drawback: They induce a strong immune response, which excludes them from clinical trials. Results: In the past few years, there have been substantial efforts to improve adenoviral vectors with particular emphasis on reducing immunological effects in the host organism. Conclusions: In this review we describe the preparation and application of gutless vectors, the most advanced and promising type of adenoviral vehicles so far.
Abstract
deZusammenfassung: Grundlagen: Der Erfolg einer Gentherapie hängt von der Etablierung geeigneter Gentransfermethoden ab. Die effektivsten Transportmittel für Fremdgene zum Zielgewebe vermitteln modifizierte Adenoviren. Methodik: Die erste Generation von adenoviralen Vektoren haben ungeachtet der hohen Infektiosität einen essentiellen Nachteil: sie induzieren eine starke Immunantwort, die sie von klinischen Versuchen ausschließt. Ergebnisse: In den letzten Jahren gab es verstärkte Bemühungen, die adenoviralen Vektoren zu verbessern und im Besonderen die immunologischen Effekte an dem Empfängerorganismus zu reduzieren. Schlußfolgerungen: Hier beschreiben wir die Präparation und Applikation von „Gutless”-Vektoren, den bisher bestentwickelten und vielversprechendsten adenoviralen Vektoren.
References
- 1 Armentano D, Sookdeo CC, Hehir KM, Gregory RJ, St George JA, Pronce GA, Wadsworth SC, Smith AE: Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gen Ther 1995; 6: 1343 – 1353.
- 2 Benihound K, Yeh P, Perricaudet M: Adenovirus vector for gene delivery. Curr Opin Biotech 1999; 10: 440 – 447.
- 3 Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320 – 1323.
- 4 Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546 – 549.
- 5 Chan L: Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Curr Opin Lipidol 1995; 6: 335 – 340.
- 6 Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR: Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997; 94: 1645 – 1650.
- 7 Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnic N, Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401 – 1405.
- 8 Dong JY, Wang D, Van Ginkel FW, Pasqual DW, Frizzell RA: Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7: 319 – 331.
- 9 Dusetti NJ, Vasseur S, Ortiz EM, Romeo H, Dagorn JC, Burrone O, Iovanna JL: The pancreatitis-associated protein I promoter allows targeting to the pancreas of foreign gene, whose expression is up-regulated during pancreatic inflammation. J Biol Chem 1997; 272: 5800 – 5804.
- 10 Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11 – 22.
- 11 Gerard RD, Chan L: Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol 1996; 7: 105 – 111.
- 12 Gerard RD, Collen D: Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. Cardiovasc Res 1997; 35: 451 – 458.
- 13 Gilbert R, Nalbantoglu J, Howell JM, Davies L, Fletcher S, Amalfitano A, Petrof BJ, Kamen A, Massie B, Karpati G: Dystrophin expression in muscle following gene expression with a fully deleted (‘gutted’) adenovirus is markedly improved by transacting adenoviral gene products. Hum Gene Ther 2001; 12: 1741 – 1755.DOI: 10.1089/104303401750476249
- 14 Goldman MJ, Litzky LA, Engelhardt JF, Wilson JM: Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther 1995; 6: 839 – 851.
- 15 Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ III, Stein EA, Lupien PJ, Brewer HB Jr, Raper SE: A pilot study of ex-vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1995; 1: 1148 – 1154.
- 16 Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DBJ, Greelish JP, Mitchell MA, Wells A, Sweeney HL, Wilson JM: In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996; 7: 1907 – 1914.
- 17 Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, Dec GW, Semigran MJ, Rosenzweig A: Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998; 95: 5251 – 5256.
- 18 Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML: Construction of adenovirus vector through cre-lox recombination. J Virol 1997; 71: 1842 – 1849.
- 19 Hertz J, Gerard RD: Adenovirus-mediated low density lipoprotein receptor gene transfer accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812 – 2816.
- 20 Hoffman EP, Brown JRH, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919 – 928.
- 21 Huang S, Endo RI, Nemerow GR: Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257 – 2263.
- 22 Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I: Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377 – 11382.
- 23 Kajinam I, Mabuchi H: Therapeutic effect of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipidol 1999; 10: 401 – 406.DOI: 10.1097/00041433-199910000-00004
- 24 Kass-Eisler A, Leinwand LA: DNA- and adenovirus-mediated gene transfer into cardiac muscle. Methods Cell Biol 1997; 52: 423 – 437.
- 25 Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L: Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282 – 13287.
- 26 Kobayashi K, Oka K, Forte T, Shida B, Teng B, Ishimura-Oka K, Nakamuta M, Chan L: Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996; 271: 6852 – 6860.
- 27 Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Aad Sci USA 1996; 93: 5731 – 5736.
- 28 Kovesdi I, Brough DE, Bruder JT, Wickham TJ: Adenoviral vectors for gene transfer. Curr Opin Biotechnol 1997; 8: 583 – 589.
- 29 Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N, Savino R: Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 2000; 11: 859 – 868.
- 30 Maione D, Rocca CD, Giannetti P, D'Arrigo R, Liberatosciolo L, Franlin LL, Sandig V, Ciliberto G, La Monica N, Savino R: An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001; 98: 5986 – 5991.
- 31 Mitani K, Graham FL, Caskey CT, Kochanek S: Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995; 95: 3854 – 3858.
- 32 Morral N, Parks R, Zhou H, Langston C, Schiedner G, Quinones J, Graham FL, Kochanek S, Beaudet AL: High doses of a helper-dependent adenoviral vector yield supraphysiological levels of a alpha1-antitripsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709 – 2716.
- 33 Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aquilar-Cordova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL: Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816 – 12821.
- 34 Morsy MA, Gu MC, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT: An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866 – 7871.
- 35 Morsy MA, Gu MC, Zhao JZ, Holder DJ, Rogers IT, Pouch WJ, Motzel SL, Klein HJ, Gupta SK, Liang X, Tota MR, Rosenblum CI, Caskey CT: Leptin gene therapy and daily protein administration: a comparative study in the ob/ob mouse. Gene Ther 1998; 5: 8 – 18.
- 36 Mountain A: Gene therapy: the first decade. TIBTECH 2000; 18: 119 – 128.
- 37 Oka K, Pastore L, Kim IH, Merched A, Nomura S, Lee HJ, Merched-Sauvage M, Arden-Riley C, Lee B, Finegold M, Beaudet A, Chan L: Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103: 1274 – 1282.
- 38 Parks R, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL: A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565 – 13570.
- 39 Parks R, Evelegh C, Graham F: Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999; 6: 1565 – 1673.
- 40 Peng Y, Trevejo J, Zhou J, Marino MW, Crystal RG, Falck-Pedersen E, Elkon KB: Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J Virol 1999; 73: 5098 – 5109.
- 41 Piedra PA, Poveda GA, Ramscy B, McCoy K, Hiatt PW: Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998; 101: 1013 – 1019.
- 42 Sandig V, Youil R, Bett AJ, Franlin LL, Oshima M, Maione D, Wang F, Metzker ML, Savino R, Cakey CT: Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 2000; 97: 1002 – 1007.
- 43 Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S: Genomic DNA transfer with a high-capacity adenovirus vector results in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180 – 183.
- 44 Shi Q, Wang Y, Worton R: Modulation of the specificity and activity of a cellular promoter in a adenoviral vector. Hum Gene Ther 1997; 8: 403 – 410.
- 45 St Clair RW, Beisiegel U: What do all the apolipoprotein receptors do? Curr Opin Lipidol 1997; 8: 243 – 245.
- 46 Umana P, Gerdes CA, Stone D, Davies JR, Ward D, Castro MG, Lowenstein PR: Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001; 19: 582 – 485.
- 47 Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998; 273: 2161 – 2168.
- 48 Wang Y, Huang S: Adenovirus technology for gene manipulation and functional studies. Drug Discovery Today 2000; 5: 10 – 16.DOI: 10.1016/s1359-6446(99)01433-6
- 49 Wilmott R, Amin RS, Perez CR, Wert SEM., Keller G, Boivin GP, Hirsch R, De Inocencio J, Lu P, Reising SF, Yei S, Whitsett JA, Trapnell BC: Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum Gene Ther 1996; 6: 301 – 318.
- 50 Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370 – 6377.
- 51 Zhang HG, Zhou T, Yang P, Edwards CK III, Curiel DT, Moutz DM: Inhibition of tumor necrosis factor-a decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 1998; 9: 1875 – 1884.
- 52 Zhou H, Zhao T, Pastore L, Nageh M, Zheng W, Rao XM, Beaudet AL: A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector. Mol Ther 2001; 3: 613 – 622.DOI: 10.1006/mthe.2001.0288
- 53 Zou L, Zhou H, Postore L, Yang K: Prolonged transgene expression mediated by a helper-dependent adenoviral vector (HdAd) in the central nervous system. Mol Ther 2000; 2: 105 – 113.
- 54 Zou L, Yuan X, Zhou H, Lu H, Yang K: Helper-dependent adenoviral vector-mediated gene transfer in aged rat brain. Hum Gene Ther 2001; 12: 181 – 191.
